Genetic medicine is accelerating in Japan

BACKGROUND: In 2018, BRACAnalysis® was covered by medical insurance in Japan as a companion diagnostic test for the poly ADP-ribose polymerase inhibitor olaparib. In April 2020, eligibility for BRCA1/2 genetic testing was expanded to the diagnosis of hereditary breast and ovarian cancer syndrome, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Saori, Kubo, Makoto, Kaneshiro, Kazuhisa, Kai, Masaya, Yamada, Mai, Morisaki, Takafumi, Takao, Yuka, Shimazaki, Akiko, Shikada, Sawako, Nakamura, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225975/
https://www.ncbi.nlm.nih.gov/pubmed/35191009
http://dx.doi.org/10.1007/s12282-022-01342-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225975/
https://www.ncbi.nlm.nih.gov/pubmed/35191009
http://dx.doi.org/10.1007/s12282-022-01342-4

Ejemplares similares